Genetic variants in bonafide cancer genes are a major concern for patients and health practitioners.

 

Harmful genetic variants can potentially increase an individuals' chance of developing cancer if the variants impact gene function. At Ranomics, we have developed a high-throughput synthetic lethality screening platform to test whether cancer gene (e.g. BRCA1 and BRCA2) variants impact gene function in cancer cell models. 

​

Quickly understand whether a cancer gene variant is functionally important or pharmacologically actionable using our VERG platform.